Agulnik Mark, Mason Warren P
Princess Margaret Hospital, Department of Medicine, Toronto, ON, Canada.
Curr Neurol Neurosci Rep. 2006 May;6(3):212-7. doi: 10.1007/s11910-006-0008-9.
The optimal treatment for patients with oligodendrogliomas is unknown, and current management strategies remain controversial. This past year, further exploration of the molecular genetics of the tumors and its prognostic implications for outcome, evaluation of the utility of positron emission tomography imaging, and the role of radiation and chemotherapy in the treatment of oligodendrogliomas have been reported. It is becoming increasingly apparent that oligodendrogliomas are several distinct diseases on a molecular level, and that key genetic derangements can signify a response to treatment and favorable outcome. The added contributions of recent publications consolidates these emerging impressions. Ultimately, the combination of improved imaging techniques, molecular profiling, and new therapies should result in improved outcome with reduced treatment-related toxicity for patients with newly diagnosed, progressive, and recurrent oligodendrogliomas.
少突胶质细胞瘤患者的最佳治疗方案尚不清楚,目前的管理策略仍存在争议。过去一年,已有关于肿瘤分子遗传学及其对预后影响的进一步探索、正电子发射断层扫描成像效用的评估以及放疗和化疗在少突胶质细胞瘤治疗中的作用的报道。越来越明显的是,少突胶质细胞瘤在分子水平上是几种不同的疾病,关键的基因紊乱可以预示对治疗的反应和良好的预后。近期出版物的补充贡献巩固了这些新出现的观点。最终,改进的成像技术、分子分析和新疗法的结合应能改善新诊断、进展性和复发性少突胶质细胞瘤患者的预后,并降低与治疗相关的毒性。